Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global PD-1/PD-L1 Immunotherapy market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. From industry perspective this report analyses supply chain, including process chart introduction, upstream key raw material and cost analysis, distributor and downstream buyer analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global PD-1/PD-L1 Immunotherapy market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.
Segmented by Category
PD-1 Inhibitors
PD-L1 Inhibitors
Segmented by End User/Segment
Non-Small Cell Lung Cancer
Esophageal Cancer
Urothelial Carcinoma
Hepatocellular Carcinoma
Small Cell Lung Cancer
Others
Segmented by Country
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Spain
Asia Pacific
China
Japan
Korea
Southeast Asia
India
Australasia
Central & South America
Brazil
Argentina
Colombia
Middle East & Africa
Iran
Israel
Turkey
South Africa
Saudi Arabia
Key manufacturers included in this survey
Sanofi S.A.
Regeneron Pharmaceuticals Inc.
Pfizer Inc.
Novartis AG
Merck & Co., Inc.
Jiangsu HengRui Medicine Co., Ltd.
Innovent Biologics, Inc.
GlaxoSmithKline plc
F. Hoffmann-La Roche Ltd
Eli Lilly & Company
Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
Bristol-Myers Squibb Company
BeiGene, Ltd.
AstraZeneca Plc
Table of Contents1 Product Introduction and Overview 1.1 Product Definition 1.2 Product Specification 1.3 Global Market Overview 1.3.1 Global PD-1/PD-L1 Immunotherapy Market Status and Forecast (2016-2027) 1.3.2 Global PD-1/PD-L1 Immunotherapy Sales Value CAGR by Region 1.4 Market Drivers, Inhibitors 1.4.1 Market Drivers 1.4.2 Market Inhibitors 1.4.3 COVID-19 Impact Analysis2 Global PD-1/PD-L1 Immunotherapy Supply by Company 2.1 Global PD-1/PD-L1 Immunotherapy Sales Volume by Company 2.2 Global PD-1/PD-L1 Immunotherapy Sales Value by Company 2.3 Global PD-1/PD-L1 Immunotherapy Price by Company 2.4 PD-1/PD-L1 Immunotherapy Production Location and Sales Area of Main Manufacturers 2.5 Trend of Concentration Rate3 Global and Regional PD-1/PD-L1 Immunotherapy Market Status by Category 3.1 PD-1/PD-L1 Immunotherapy Category Introduction 3.1.1 PD-1 Inhibitors 3.1.2 PD-L1 Inhibitors 3.2 Global PD-1/PD-L1 Immunotherapy Market by Category 3.2.1 Global PD-1/PD-L1 Immunotherapy Sales Volume by Category (2016-2021) 3.2.2 Global PD-1/PD-L1 Immunotherapy Sales Value by Category (2016-2021) 3.2.3 Global PD-1/PD-L1 Immunotherapy Price by Category (2016-2021) 3.3 North America: by Category 3.4 Europe: by Category 3.5 Asia Pacific: by Category 3.6 Central & South America: by Category 3.7 Middle East & Africa: by Category4 Global and Regional PD-1/PD-L1 Immunotherapy Market Status by End User/Segment 4.1 PD-1/PD-L1 Immunotherapy Segment by End User/Segment 4.1.1 Non-Small Cell Lung Cancer 4.1.2 Esophageal Cancer 4.1.3 Urothelial Carcinoma 4.1.4 Hepatocellular Carcinoma 4.1.5 Small Cell Lung Cancer 4.1.6 Others 4.2 Global PD-1/PD-L1 Immunotherapy Market by End User/Segment 4.2.1 Global PD-1/PD-L1 Immunotherapy Sales Volume by End User/Segment (2016-2021) 4.2.2 Global PD-1/PD-L1 Immunotherapy Sales Value by End User/Segment (2016-2021) 4.2.3 Global PD-1/PD-L1 Immunotherapy Price by End User/Segment (2016-2021) 4.3 North America: by End User/Segment 4.4 Europe: by End User/Segment 4.5 Asia Pacific: by End User/Segment 4.6 Central & South America: by End User/Segment 4.7 Middle East & Africa: by End User/Segment5 Global PD-1/PD-L1 Immunotherapy Market Status by Region 5.1 Global PD-1/PD-L1 Immunotherapy Market by Region 5.1.1 Global PD-1/PD-L1 Immunotherapy Sales Volume by Region 5.1.2 Global PD-1/PD-L1 Immunotherapy Sales Value by Region 5.2 North America PD-1/PD-L1 Immunotherapy Market Status 5.3 Europe PD-1/PD-L1 Immunotherapy Market Status 5.4 Asia Pacific PD-1/PD-L1 Immunotherapy Market Status 5.5 Central & South America PD-1/PD-L1 Immunotherapy Market Status 5.6 Middle East & Africa PD-1/PD-L1 Immunotherapy Market Status6 North America PD-1/PD-L1 Immunotherapy Market Status 6.1 North America PD-1/PD-L1 Immunotherapy Market by Country 6.1.1 North America PD-1/PD-L1 Immunotherapy Sales Volume by Country (2016-2021) 6.1.2 North America PD-1/PD-L1 Immunotherapy Sales Value by Country (2016-2021) 6.2 United States 6.3 Canada 6.4 Mexico7 Europe PD-1/PD-L1 Immunotherapy Market Status 7.1 Europe PD-1/PD-L1 Immunotherapy Market by Country 7.1.1 Europe PD-1/PD-L1 Immunotherapy Sales Volume by Country (2016-2021) 7.1.2 Europe PD-1/PD-L1 Immunotherapy Sales Value by Country (2016-2021) 7.2 Germany 7.3 France 7.4 UK 7.5 Italy 7.6 Russia 7.7 Spain8 Asia Pacific PD-1/PD-L1 Immunotherapy Market Status 8.1 Asia Pacific PD-1/PD-L1 Immunotherapy Market by Country 8.1.1 Asia Pacific PD-1/PD-L1 Immunotherapy Sales Volume by Country (2016-2021) 8.1.2 Asia Pacific PD-1/PD-L1 Immunotherapy Sales Value by Country (2016-2021) 8.2 China 8.3 Japan 8.4 Korea 8.5 Southeast Asia 8.6 India 8.7 Australasia9 Central & South America PD-1/PD-L1 Immunotherapy Market Status 9.1 Central & South America PD-1/PD-L1 Immunotherapy Market by Country 9.1.1 Central & South America PD-1/PD-L1 Immunotherapy Sales Volume by Country (2016-2021) 9.1.2 Central & South America PD-1/PD-L1 Immunotherapy Sales Value by Country (2016-2021) 9.2 Brazil 9.3 Argentina 9.4 Colombia10 Middle East & Africa PD-1/PD-L1 Immunotherapy Market Status 10.1 Middle East & Africa PD-1/PD-L1 Immunotherapy Market by Country 10.1.1 Middle East & Africa PD-1/PD-L1 Immunotherapy Sales Volume by Country (2016-2021) 10.1.2 Middle East & Africa PD-1/PD-L1 Immunotherapy Sales Value by Country (2016-2021) 10.2 Iran 10.3 Israel 10.4 Turkey 10.5 South Africa 10.8 Saudi Arabia11 Supply Chain and Manufacturing Cost Analysis 11.1 Supply Chain Analysis 11.2 Production Process Chart Analysis 11.3 Raw Materials and Key Suppliers Analysis 11.3.1 Raw Materials Introduction 11.3.2 Raw Materials Key Suppliers List 11.4 PD-1/PD-L1 Immunotherapy Manufacturing Cost Analysis 11.5 PD-1/PD-L1 Immunotherapy Sales Channel and Distributors Analysis 11.5.1 PD-1/PD-L1 Immunotherapy Sales Channel 11.5.2 PD-1/PD-L1 Immunotherapy Distributors 11.6 PD-1/PD-L1 Immunotherapy Downstream Major Buyers12 Global PD-1/PD-L1 Immunotherapy Market Forecast by Category and by End User/Segment 12.1 Global PD-1/PD-L1 Immunotherapy Sales Volume and Sales Value Forecast (2022-2027) 12.2 Global PD-1/PD-L1 Immunotherapy Forecast by Category 12.2.1 Global PD-1/PD-L1 Immunotherapy Sales Volume Forecast by Category 12.2.2 Global PD-1/PD-L1 Immunotherapy Sales Value Forecast by Category 12.2.3 Global PD-1/PD-L1 Immunotherapy Price Forecast by Category 12.3 Global PD-1/PD-L1 Immunotherapy Forecast by End User/Segment 12.3.1 Global PD-1/PD-L1 Immunotherapy Sales Volume Forecast by End User/Segment 12.3.2 Global PD-1/PD-L1 Immunotherapy Sales Value Forecast by End User/Segment 12.3.3 Global PD-1/PD-L1 Immunotherapy Price Forecast by End User/Segment13 Global PD-1/PD-L1 Immunotherapy Market Forecast by Region/Country 13.1 Global PD-1/PD-L1 Immunotherapy Market Forecast by Region (2022-2027) 13.1.1 Global PD-1/PD-L1 Immunotherapy Sales Volume Forecast by Region (2022-2027) 13.1.2 Global PD-1/PD-L1 Immunotherapy Sales Value Forecast by Region (2022-2027) 13.2 North America Market Forecast 13.3 Europe Market Forecast 13.4 Asia Pacific Market Forecast 13.5 Central & South America Market Forecast 13.6 Middle East & Africa Market Forecast14 Key Participants Company Information 14.1 Sanofi S.A. 14.1.1 Company Information 14.1.2 PD-1/PD-L1 Immunotherapy Product Introduction 14.1.3 Sanofi S.A. PD-1/PD-L1 Immunotherapy Sales Volume, Price, Sales Value and Gross Margin (2019-2021) 14.1.4 SWOT Analysis 14.2 Regeneron Pharmaceuticals Inc. 14.2.1 Company Information 14.2.2 PD-1/PD-L1 Immunotherapy Product Introduction 14.2.3 Regeneron Pharmaceuticals Inc. PD-1/PD-L1 Immunotherapy Sales Volume, Price, Sales Value and Gross Margin (2019-2021) 14.2.4 SWOT Analysis 14.3 Pfizer Inc. 14.3.1 Company Information 14.3.2 PD-1/PD-L1 Immunotherapy Product Introduction 14.3.3 Pfizer Inc. PD-1/PD-L1 Immunotherapy Sales Volume, Price, Sales Value and Gross Margin (2019-2021) 14.3.4 SWOT Analysis 14.4 Novartis AG 14.4.1 Company Information 14.4.2 PD-1/PD-L1 Immunotherapy Product Introduction 14.4.3 Novartis AG PD-1/PD-L1 Immunotherapy Sales Volume, Price, Sales Value and Gross Margin (2019-2021) 14.4.4 SWOT Analysis 14.5 Merck & Co., Inc. 14.5.1 Company Information 14.5.2 PD-1/PD-L1 Immunotherapy Product Introduction 14.5.3 Merck & Co., Inc. PD-1/PD-L1 Immunotherapy Sales Volume, Price, Sales Value and Gross Margin (2019-2021) 14.5.4 SWOT Analysis 14.6 Jiangsu HengRui Medicine Co., Ltd. 14.6.1 Company Information 14.6.2 PD-1/PD-L1 Immunotherapy Product Introduction 14.6.3 Jiangsu HengRui Medicine Co., Ltd. PD-1/PD-L1 Immunotherapy Sales Volume, Price, Sales Value and Gross Margin (2019-2021) 14.6.4 SWOT Analysis 14.7 Innovent Biologics, Inc. 14.7.1 Company Information 14.7.2 PD-1/PD-L1 Immunotherapy Product Introduction 14.7.3 Innovent Biologics, Inc. PD-1/PD-L1 Immunotherapy Sales Volume, Price, Sales Value and Gross Margin (2019-2021) 14.7.4 SWOT Analysis 14.8 GlaxoSmithKline plc 14.8.1 Company Information 14.8.2 PD-1/PD-L1 Immunotherapy Product Introduction 14.8.3 GlaxoSmithKline plc PD-1/PD-L1 Immunotherapy Sales Volume, Price, Sales Value and Gross Margin (2019-2021) 14.8.4 SWOT Analysis 14.9 F. Hoffmann-La Roche Ltd 14.9.1 Company Information 14.9.2 PD-1/PD-L1 Immunotherapy Product Introduction 14.9.3 F. Hoffmann-La Roche Ltd PD-1/PD-L1 Immunotherapy Sales Volume, Price, Sales Value and Gross Margin (2019-2021) 14.9.4 SWOT Analysis 14.10 Eli Lilly & Company 14.10.1 Company Information 14.10.2 PD-1/PD-L1 Immunotherapy Product Introduction 14.10.3 Eli Lilly & Company PD-1/PD-L1 Immunotherapy Sales Volume, Price, Sales Value and Gross Margin (2019-2021) 14.10.4 SWOT Analysis 14.11 Chia Tai Tianqing Pharmaceutical Group Co. Ltd. 14.12 Bristol-Myers Squibb Company 14.13 BeiGene, Ltd. 14.14 AstraZeneca Plc15 Conclusion16 Methodology